Research Paper Volume 12, Issue 24 pp 25101—25119
Could microtubule inhibitors be the best choice of therapy in gastric cancer with high immune activity: mutant DYNC1H1 as a biomarker
Figure 7. Work flow of the study. DEGs: differentially expressed genes; TMB-H: high tumor mutational burden; MSI-H: high microsatellite instability; GSEA: gene sets enrichment analysis; GDSC: genomics of drug sensitivity in cancer; PPI: protein-protein interaction; TCGA: The Cancer Genome Atlas; NCI-60: National Cancer Institute 60.